Lipid-lowering agents in solid organ transplant recipients

Area of Science:

• Cardiology
• Nephrology
• Transplantation Medicine

Background:

• Dyslipidaemia is a prevalent, modifiable risk factor for cardiovascular events in solid organ transplant (SOT) recipients.
• It is often underdiagnosed and undertreated, with associated risks of cardiovascular events, acute rejection, and vasculopathy being underestimated.
• Immunosuppressants are a primary cause of dyslipidaemia in SOT patients, necessitating cautious management.

Purpose of the Study:

• To review current and future management strategies for lipid disorders in SOT recipients.
• To propose a clinical algorithm for lipid management.
• To highlight the potential of novel lipid-lowering therapies (LLTs) and encourage further research.

Main Methods:

• Literature review of current and emerging lipid-lowering therapies.
• Discussion of challenges in statin use (non-adherence, drug interactions).
• Emphasis on a multidisciplinary team approach for comprehensive care.

Main Results:

• Novel LLTs like PCSK9 inhibitors and bempedoic acid, along with combination therapy (ezetimibe/statin), show promise for safe and effective LDL-C reduction.
• Improved adherence and outcomes are anticipated with these evolving treatment options.
• The need for tailored lipid treatment targets based on organ type and cardiovascular risk is highlighted.

Conclusions:

• A structured, multidisciplinary approach is essential for optimal lipid management in complex SOT patients.
• Novel LLTs and combination therapies offer improved efficacy and adherence.
• Further trials and registries are needed to validate initial combination therapy strategies and assess the clinical impact of novel LLTs.